Allianz SE Invests $90,000 in BioNTech SE (NASDAQ:BNTX)

Allianz SE acquired a new stake in BioNTech SE (NASDAQ:BNTX) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 800 shares of the company’s stock, valued at approximately $90,000.

Other large investors have also bought and sold shares of the company. BIT Capital GmbH boosted its position in shares of BioNTech by 13.9% during the 4th quarter. BIT Capital GmbH now owns 19,480 shares of the company’s stock valued at $2,220,000 after purchasing an additional 2,370 shares in the last quarter. LPL Financial LLC boosted its holdings in BioNTech by 4.9% during the fourth quarter. LPL Financial LLC now owns 38,860 shares of the company’s stock worth $4,428,000 after buying an additional 1,800 shares in the last quarter. Lingohr Asset Management GmbH acquired a new position in BioNTech in the fourth quarter worth approximately $357,000. Midwest Professional Planners LTD. increased its holdings in shares of BioNTech by 5.8% in the fourth quarter. Midwest Professional Planners LTD. now owns 4,051 shares of the company’s stock valued at $462,000 after buying an additional 222 shares in the last quarter. Finally, LBP AM SA lifted its position in shares of BioNTech by 2.1% during the 4th quarter. LBP AM SA now owns 252,918 shares of the company’s stock valued at $28,820,000 after acquiring an additional 5,085 shares during the last quarter. Institutional investors own 15.52% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on BNTX shares. Morgan Stanley decreased their target price on BioNTech from $145.00 to $139.00 and set an “overweight” rating on the stock in a report on Tuesday, March 11th. Wells Fargo & Company started coverage on BioNTech in a research note on Wednesday, December 11th. They issued an “overweight” rating and a $170.00 price target on the stock. BMO Capital Markets upped their price objective on shares of BioNTech from $130.00 to $143.00 and gave the company an “outperform” rating in a research note on Tuesday, March 11th. Truist Financial initiated coverage on shares of BioNTech in a report on Friday, January 10th. They issued a “buy” rating and a $172.00 target price for the company. Finally, Canaccord Genuity Group restated a “buy” rating and set a $171.44 price target on shares of BioNTech in a report on Tuesday, March 11th. Three analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $143.73.

BioNTech Trading Down 4.1 %

BioNTech stock opened at $91.06 on Tuesday. BioNTech SE has a 12 month low of $76.53 and a 12 month high of $131.49. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. The stock has a market cap of $21.85 billion, a P/E ratio of -43.36 and a beta of 0.30. The company’s fifty day simple moving average is $110.99 and its 200-day simple moving average is $113.65.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings data on Monday, March 10th. The company reported $1.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.38 by $0.70. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The firm had revenue of $1.19 billion during the quarter, compared to analysts’ expectations of $1.24 billion. During the same quarter last year, the firm earned $1.90 earnings per share. The business’s revenue for the quarter was down 19.5% on a year-over-year basis. As a group, sell-side analysts forecast that BioNTech SE will post -3.88 EPS for the current fiscal year.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.